Fenwick Represents Alpine Immune Sciences in Pending Acquisition by Vertex Pharmaceuticals

Fenwick is representing Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company dedicated to discovering and developing innovative, protein-based immunotherapies, in its pending acquisition by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX).

Under the terms of the agreement, Vertex will acquire all the outstanding shares of Alpine for $65 per share, for an aggregate value of approximately $4.9 billion. The transaction has been unanimously approved by both of the Alpine and Vertex Boards of Directors and is expected to close in the second quarter of 2024, subject to the tender of a majority of the outstanding shares of Alpine common stock, the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. More information can be obtained from Alpine Immune Sciences' announcement.

The Fenwick transaction team included corporate partners Doug Cogen, Effie Toshav, Victoria Lupu, Amanda Rose and Rob Freedman, counsel Chelsea Anderson and associates Rob O’Connor, Jordan Beals, Philip Ewing, Arielle Trapp, Meg Moloney, Stephanie Maynes Aldous, Warren Pugash, Blair Mills, and Max Krinsky; technology transactions partner Stefano Quintini and associates Jennifer Yoon, Kehl Sink and Sam Dodson; executive compensation partner Matt Cantor and associate Cynthia Yuan; antitrust partner Tom Ensign and associates Elizabeth Suarez and Kaylynn Moss; healthcare regulatory partner Jennifer Yoo; tax partner Larissa Neumann and associate Kris Hatch; and privacy counsels Melanie Jolson and Sari Ratican and associate Mudasar Khan.